Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: sam_o who wrote (67979)	8/15/2002 6:28:03 PM
From: sam_o	Respond to of 208838

This was released toDAY.... after the close?? 4:33PM MedImmune lowers guidance (MEDI) 29.18 -0.61: Co lowers its Q3 guidance to a cash loss per share of $0.15-$0.16, vs consensus of a loss of $0.12; cash EPS for 2002 is expected to be $0.62-$0.67; co says its change in financial outlook is due to costs associated with the in-licensing of the human metapneumovirus research program and an increase in R&D costs; also, co says that "in the event FluMist is not approved and launched in 2002, $0.25-$0.27 per share would need to be deducted from cash and GAAP EPS guidance". Comments... ?? A ploy to lower the stock so additional insiders could jump on.. or???